By enGenes Biotech…
enGenes Biotech returning to CPHI Worldwide in Milan
Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech is returning with its advanced proprietary high-yield expression technologies to Europe’s leading pharma industry event, the CPHI Worldwide trade expo, hosted in Milan for 2024.
enGenes will again attend CPHI as a visitor, with its team, including Mr. Karl Hübler, lead of the Business Development team, networking across the show.
Enhanced production opportunities
“We were very impressed with CPHI Worldwide on our debut at last year’s Barcelona expo and delighted with the number of new conversations we were able to start there,” said CEO and co-founder Dr. Jürgen Mairhofer.
“Once again, we hope to take advantage of CPHI’s multiple connection opportunities to find new partners who can benefit from our -eXpress™ growth decoupled E. coli-based expression system for superior protein production, as well related enhanced biologics production technologies like -eXcite™ and -eXpand™.”
The enGenes team will also emphasize the influential role of -eXpress™ and -eXcite™ in the drive towards greener continuous production of biologics, as part of the ECOnti consortium.
About enGenes Biotech
enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading-edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of the current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.
enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes -eXpress™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes -eXpress™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.
enGenes Biotech offers development and manufacturing services tailored to the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.
Find out more at: https://www.engenes.cc
About CPHI Milan 2024
Now in its 35th year, CPHI continues as the flagship European annual trade show for pharma ingredients and partner sourcing, with a refreshed mission to be the industry’s main enabler for sustainability, whilst also being an environmentally and socially responsible event.
The recently rebranded expo now uses a hybrid model that fuses one of Europe’s largest physical expos with an online dimension to make networking and browsing easier and to extend the time frame of the event indefinitely.
For 2024, CPHI Milan is a three-day event opening October 8 at the Fiera Milano convention center, with the online dimension now accessible all year round.
The newly integrated main CPHI event features exhibitor zones for Machinery & Equipment, Finished Dosage, Packaging & Drug Delivery, Contract Manufacturing & Services, APIs, Excipients, Integrated Pharma, Natural extracts, and Fine Chemicals.
CPHI Milano is organised by Informa Markets with further information at: https://www.cphi.com/europe/en/home.html
Resources
Click on enGenes secures significant funding for ECOnti E. Coli Continuous Manufacturing Project for further information.